症状性阿尔茨海默病患者血浆可溶性淀粉样前体蛋白 β 水平。
Plasma levels of soluble amyloid precursor protein β in symptomatic Alzheimer's disease.
机构信息
Department of Psychiatry and Psychotherapy, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany.
Department of Psychiatry, University Hospital of Rion, University of Patras, 26500, Patras, Greece.
出版信息
Eur Arch Psychiatry Clin Neurosci. 2018 Aug;268(5):519-524. doi: 10.1007/s00406-017-0815-9. Epub 2017 Jun 10.
The established biomarkers of Alzheimer's disease (AD) require invasive endeavours or presuppose sophisticated technical equipment. Consequently, new biomarkers are needed. Here, we report that plasma levels of soluble amyloid precursor protein β (sAPPβ), a protein of the initial phase of the amyloid cascade, were significantly lower in patients with symptomatic AD (21 with mild cognitive impairment due to AD and 44 with AD dementia) with AD-typical cerebral hypometabolic pattern compared with 27 cognitively healthy elderly individuals without preclinical AD. These findings yield further evidence for the potential of sAPPβ in plasma as an AD biomarker candidate.
阿尔茨海默病（AD）的既定生物标志物需要侵入性的努力或预先假设复杂的技术设备。因此，需要新的生物标志物。在这里，我们报告称，在有症状的 AD 患者（21 名轻度认知障碍归因于 AD，44 名 AD 痴呆）中，血浆可溶性淀粉样前体蛋白 β（sAPPβ）水平明显低于具有 AD 典型脑低代谢模式的患者，而认知健康的老年人中没有临床前 AD 的患者为 27 名。这些发现进一步证明了血浆中 sAPPβ作为 AD 生物标志物候选物的潜力。
Zotero 插件